Your browser doesn't support javascript.
loading
A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
Sanchez, Jackee N; Subramanian, Chitra; Chanda, Monica; Shanguan, Gary; Zhang, Nina; Wang, Ton; Timmermann, Barbara N; Blagg, Brian S J; Cohen, Mark S.
Afiliação
  • Sanchez JN; Department of Pharmacology.
  • Subramanian C; Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Chanda M; Department of Pharmacology.
  • Shanguan G; Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Zhang N; Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Wang T; Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Timmermann BN; Department of Medicinal Chemistry, University of Kansas, Lawrence, Kansas.
  • Blagg BSJ; Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana, USA.
  • Cohen MS; Department of Surgery, University of Michigan, Ann Arbor, Michigan.
Melanoma Res ; 31(3): 197-207, 2021 06 01.
Article em En | MEDLINE | ID: mdl-33904516
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilonitrila / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Choque Térmico HSP90 / Proteínas Proto-Oncogênicas B-raf / Compostos de Anilina / Melanoma Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acrilonitrila / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas de Choque Térmico HSP90 / Proteínas Proto-Oncogênicas B-raf / Compostos de Anilina / Melanoma Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article